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Abstract
Background: Patterns of decreasing malaria transmission intensity make presumptive treatment of malaria an
unjustifiable approach in many African settings. The controlled use of anti-malarials after laboratory confirmed
diagnosis is preferable in low endemic areas. Diagnosis may be facilitated by malaria rapid diagnostic tests (RDTs).
In this study, the impact of a government policy change, comprising the provision of RDTs and advice to restrict
anti-malarial treatment to RDT-positive individuals, was assessed by describing diagnostic behaviour and treatment
decision-making in febrile outpatients <10 years of age in three hospitals in the Kagera and Mwanza Region in
northern Tanzania.
Methods: Prospective data from Biharamulo and Rubya Designated District Hospital (DDH) were collected before
and after policy change, in Sumve DDH no new policy was implemented. Diagnosis of malaria was confirmed by
RDT; transmission intensity was evaluated by a serological marker of malaria exposure in hospital attendees.
Results: Prior to policy change, there was no evident association between the actual level of transmission intensity
and drug-prescribing behaviour. After policy change, there was a substantial decrease in anti-malarial prescription
and an increase in prescription of antibiotics. The proportion of parasite-negative individuals who received anti-
malarials decreased from 89.1% (244/274) to 38.7% (46/119) in Biharamulo and from 76.9% (190/247) to 10.0% (48/
479) in Rubya after policy change.
Conclusion: This study shows that an official policy change, where RDTs were provided and healthcare providers
were advised to adhere to RDT results in prescribing drugs can be followed by more rational drug-prescribing
behaviour. The current findings are promising for improving treatment policy in Tanzanian hospitals.
Background
Malaria accounts for more than 800,000 deaths a year
worldwide [1], of which 90% are in young African chil-
dren [2]. It is the leading cause of health service atten-
dance in Tanzania and comprises ~40% of all morbidity
in Tanzanian outpatients below five years of age [3].
This poses a considerable burden on health systems.
Since the 1980s, malaria control has incorporated pre-
sumptive treatment of fever with anti-malarials, treating
all febrile episodes suspected of malaria with a full ther-
apeutic dose of anti-malarials, chloroquine (CQ, until
2001 in Tanzania [4]) or sulphadoxine-pyrimethamine
(SP, until 2007 [5]). This strategy was implemented to
effectively treat true cases of malaria and may also have
had beneficial effects on malaria transmission by effec-
tively providing chemoprophylaxis to children in malaria
endemic areas [6]. However, presumptive treatment may
no longer be a justifiable approach in all settings now it
is realized that many parts of Africa are characterized by
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sion intensity is decreasing in many areas in sub-
Saharan Africa [9-12]. In such settings, presumptive
treatment will lead to substantial over-treatment [8],
which is particularly important now the relatively expen-
sive artemisinin-combination therapy (ACT) is endorsed
as first-line treatment [13-15]. Beside expenses, such
practice will lead to a reduced susceptibility of parasites
to ACT because of the uncontrolled use of artemisinins
[16]. It is important that diagn o s i si se s t a b l i s h e db e f o r e
ACT is prescribed.
Microscopy is the gold standard method for diagnosis
of malaria, but the provision of microscopic facilities
may not always result in accurate diagnosis [2,8,14,17].
Malaria rapid diagnostic testing (RDT) forms an attrac-
tive alternative to routine microscopy with good sensi-
tivity and specificity profiles [1,18] and more objective
results. Wide-scale implementation of RDTs may, there-
fore, improve malaria diagnosis. This was acknowledged
by the Tanzanian Ministry of Health and Social Welfare.
The Kagera Region was the first in Tanzania where a
policy change was implemented as a pilot to tackle the
problem of malaria over-diagnosis. Malaria rapid diag-
nostic testing replaced routine microscopy as the main
diagnostic tool and clinicians were advised to restrict
treatment to RDT positive individuals only.
Here, the impact of the policy change was assessed by
describing diagnostic behaviour and treatment decision-
making in febrile outpatients under 10 years of age in
three hospitals in the Kagera and Mwanza Region in
Tanzania. Transmission intensity in these areas, all
nearby Lake Victoria, was assessed by serological mar-
kers of malaria exposure.
Methods
Study site
In this study, common practices in fever diagnosis in the
outpatient departments were described for three desig-
nated district hospitals (DDH) in northern Tanzania:
Biharamulo DDH and Rubya DDH, both situated in the
Kagera Region, and Sumve DDH, situated in the
Mwanza Region. Biharamulo is situated at 1,490 m,
Rubya at >1,500 m and Sumve at 1,100 m. The trans-
mission intensity of the catchment areas is suspected to
be different based on their distance to Lake Victoria and
altitude [19]. However, no formal assessments of trans-
mission intensity have been reported.
Healthcare at these outpatient departments was largely
provided by clinical officers with two to three years’
clinical training. Pneumonia, HIV, tuberculosis, gastroin-
testinal infections, various parasite infections and
malaria are common conditions in outpatients according
to hospital records. Malaria transmission is related to
the long rains in March-April and the less reliable short
rains in October -November. The study was approved
by the Kilimanjaro Christian Medical Centre Research
Ethics Committee. Written informed consent was
obtained from parents or care-takers of all participants.
Prospective data before and after policy change
Data were prospectively gathered from all patients under
the age of 10 years presenting at the outpatient depart-
ment of Sumve DDH with reported or measured fever
in the months September 2009 - January 2010. In Bihar-
amulo DDH and Rubya DDH, identical data were col-
lected in September - October 2009. This is the period
before the policy change when microscopy was the only
available tool to diagnose malaria. At the end of October
2009, the Kagera Region was the first region in Tanzania
where a policy change was implemented by the National
Malaria Control Programme (NMCP) of the Ministry of
Health and Social Welfare. This policy change com-
prised the replacement of microscopy as the main diag-
nostic tool for malaria by RDTs (ICT Malaria Pf
Cassette Test (ML01), ICT Diagnostics) with a sensitiv-
ity of 82% at parasite densities of 200 parasites/μL, of
97% for parasite densities >2000 parasites/μL and a false
positivity rate of ~1% [20]. Clinical officers were now
strictly advised to only treat RDT positive individuals
with anti-malarials; the advice was to look for alternative
diagnoses in RDT-negative individuals. The medical offi-
cers in charge received training from government offi-
cials about the implementation of the policy change.
After this, each medical officer in charge introduced the
policy change during a two-day workshop to the clinical
officers. To evaluate the short-term impact of this policy
change, data were gathered for a second period in Bihar-
amulo DDH (January 2010 - February 2010) and Rubya
DDH (October 2009 - February 2010).
The same information was collected before and after
policy change. The following information was collected
in a questionnaire: age, gender, month attending the
hospital, resident or no resident of the area in which the
hospital was situated, bed net use, use of medication in
the previous two weeks, auxiliary temperature, clinical
diagnosis made by a clinical officer, request for blood
slide, result of blood slide, treatment given in the hospi-
tal, and result of RDT. In Biharamulo and Rubya
another question ‘request for RDT’ was added in the
second period. Auxiliary temperature was measured
with digital thermometers; blood slides were prepared
according to hospital routine, stained with 10% Giemsa
solution and read by a single experienced microscopist.
Before the policy change, a finger prick blood sample
was taken for malaria parasite detection by RDT (Para-
check Pf Rapid test, Orchid Biomedical Systems) in each
patient enrolled for an objective assessment of infection
with Plasmodium falciparum.T h eR D Tw a sn o tp a r to f
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diagnosis for the current study. The RDT was used
according to the manufacturer’s instructions and is
based on the detection of histidine-rich protein II. This
RDT has a sensitivity of 75% at parasite densities of 200
parasites/μL, of 100% for parasite densities >2,000 para-
sites/μL and a false positivity rate of ~7% [20]. The
results of the RDTs were available for clinical officers
for diagnosis.
Transmission intensity
For an objective assessment of exposure to malaria,
serum samples were collected using a single finger prick
(~20 μL) from all individuals, both adults and children,
attending these three hospitals in Northern Tanzania in
November 2009. This group included patients, people
coming for routine follow-up visits and people accompa-
nying patients. This sampling method has previously
been validated to obtain a selection of samples represen-
tative of the general population in the hospital catch-
ment areas [21]. Information was collected on age,
gender, area of residency, bed net use, and use of medi-
cation in the previous two weeks.
Assessment of malaria exposure by enzyme-linked
immunosorbent assay (ELISA)
Serum was eluted from filter papers as described by
Corran et al [22]. Immunoglobulin G antibodies against
blood stage antigens were detected by indirect ELISA, as
previously described in detail [22,23] using recombinant
Apical Membrane Antigen-1 (AMA-1). AMA-1 was sug-
gested as a suitable antigen for areas of moderate or low
transmission intensity because of its high immunogeni-
city that results in saturating responses at high endemi-
city but a good discriminating power at low endemicity
[24]. To generate an OD cut-off value above which sam-
ples were deemed antibody positive, the distribution of
OD values was fitted as the sum of two Gaussian distri-
butions (assuming a narrow distribution of seronegatives
and a broader distribution of seropositives) using maxi-
mum likelihood methods [22].
Data analysis
Statistical analyses of data were performed using SPSS
version 18.0.0 and Stata 9.2 (Stata Corp, College Station
TX, USA). Categorical variables were compared
between groups by the Pearson Chi-square test or Fish-
er’s Exact test, odds ratios (OR) with 95% confidence
intervals (95% CI) were calculated. The main outcomes
of the analyses were the proportion of individuals trea-
ted with anti-malarials despite a negative RDT and the
proportion of individuals who did not receive anti-
malarials despite a positive RDT. AMA-1 ELISA
data were used to generate an age-seroprevalence plot.
OD values were expressed as percentage of the positive
control (normalized OD). The annual seroconversion
rate (SCR), l was estimated by fitting a simple model
of the acquisition and loss of antibodies to the age-
specific prevalence of the antibodies using maximum
likelihood methods assuming a binomial distribution
[23]. If visual examination of SCR suggested it was not
uniform over the whole population (i.e. there was an
obvious step in the age seroprevalence-data), models
allowing for two forces of infection profile and profile
likelihood plots were run to determine when the most
likely time for change in transmission intensity
occurred [21,25]. These resulted in a predicted time of
change in transmission, which was incorporated in the
catalytic model to generate estimates for previous and
current SRC. Models allowing for two forces of infec-
tion were preferred if the fit compared to the single
force model was significantly better by likelihood ratio
test at a p < 0.05.
Results
Collected data
From September 2009 - February 2010, a total of 1,608
outpatients below 10 years of age presenting with
(reported) fever were included. Age, reported bed net
use and socio-demographic factors were similar between
the three clinics (Table 1). The proportion of individuals
with current fever was lowest in Biharamulo.
Malaria case management before and after malaria
treatment policy change
Diagnostic behaviour and clinical management in Rubya
DDH are summarized in Figures 1 and 2; the same
information for Biharamulo DDH and Sumve DDH is
shown in Additional file 1, Additional file 2 and Addi-
tional file 3. Treatment prescribing behaviour before
and after the policy change in relation to parasite preva-
lence is shown in Table 2 for all three clinics. There
was a striking difference in RDT parasite prevalence
between the three clinics with the lowest parasite preva-
l e n c eb yR D Ti nR u b y a( 1 - 4 % )a n dt h eh i g h e s ti n
Sumve (42%, 152/362). Although the majority of RDT-
positive individuals received anti-malarial treatment, in
Biharamulo DDH, 5 malaria positive individuals did not
receive anti-malarial treatment before policy change
(8%, 5/67) compared to 2 (25%, 2/8) after policy change.
In the other health centres, a positive RDT was followed
by anti-malarial treatment in all instances. In all clinics
a substantial proportion of slide negative patients
received anti-malarial treatment before the policy
change (Sumve 67%, Biharamulo 100%, Rubya 81.1%)
and a substantial proportion of RDT negative patients
received anti-malarial treatment (Sumve 68.1%, Bihara-
mulo 89.1%, Rubya 76.9%). After the policy change this
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Rubya DDH.
There was also a striking decrease in presumptive treat-
ment of reported fever with anti-malarials. In Bihara-
mulo DDH 89.0% (284/319) of patients without a slide
taken was treated with anti-malarials before the policy
change compared to 27.0% (27/100) of patients without
a RDT after the policy change. In Rubya DDH this pro-
portion changed from 67.5% (52/77) to 2.0% (2/98),
indicating presumptive treatment was largely abandoned
after the policy change.
Management of non-malaria fevers before and after
malaria treatment policy change
Together with the decrease in anti-malarial prescription,
there was an increase in the proportion of individuals
who received antibiotics. These were mostly broad-
spectrum antibiotics like co-trimoxazole, ciproxin or
amoxicillin. In RDT negative patients in Biharamulo
DDH 12.8% received antibiotics before and 59.7% after
the policy change. In Rubya DDH the number increased
from 70.0% to 94.6%.
The estimated transmission intensity generated from
seroprevalence data
From Biharamulo DDH, Rubya DDH, and Sumve DDH,
a total of 298, 320 and 304 serum samples were success-
fully tested in the AMA-1 ELISA, respectively. The over-
all seroprevalence of AMA-1 antibodies was 52.0% (158/
304), 40.3% (129/320), and 56.7% (169/298); there was a
clear increase in seroprevalence with age in all sites (Fig-
ure 3). The seroconversion rate was highest in Sumve (l
= 0.082, 95% CI 0.063-0.11) and lowest in Rubya (l =
0.041, 95% CI 0.029 - 0.058), in line with parasite
Table 1 Characteristics of the study population
Sumve DDH Biharamulo DDH Rubya DDH
Before policy
change
After policy
change
Before policy
change
After policy
change
Study period Sep '09 - Jan '10 Sep '09 - Oct '09 Jan '10 - Feb '10 Sep '09 - Oct '09 Oct '09 - Feb '10
Number of observations 362 360 135 250 501
Age
Median (IQR) 15.0 (9.0 - 24.0) 15.0 (9.0 - 27.0) 14.5 (8.0 - 25.8) 12.0 (8.8 - 24.0) 14.0 (8.0 - 24.0)
Temperature
Mean (sd) 37.5 (1.0) 37.0 (1.0) 37.4 (1.0) 37.8 (1.0) 37.7 (1.1)
Fever (≥37.8°C), % (n/N) 39.2 (135/344) 19.1 (68/356) 29.2 (38/130) 48.4 (121/250) 46.9 (235/501)
Reported use of bed net, % (n/N) 95.8 (340/355) 98.9 (356/360) 95.5 (128/134) 95.6 (239/250) 95.2 (477/501)
Reported anti-malarial use in
preceding two weeks, % (n/N)
26.5 (95/358) 74.0 (361/488) 6.4 (48/751)
Number of serum samples
collected
308 300 320
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Figure 1 Rubya DDH before policy change. AM = anti-malarial treatment given; AB = antibiotics given; NT = no treatment installed; RDT =
rapid diagnostic test.
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mission intensity appeared to have changed over time.
While transmission intensity used to be intense (l =
0.34, 95% CI 0.19-0.61), the current SCR was similar to
that of Rubya (l = 0.019, 95% CI 0.011-0.035), indicat-
ing low transmission intensity.
Discussion
In three study areas in the vicinity of Lake Victoria, a
considerable overuse of anti-malarials was seen prior to
a new government policy to incorporate RDTs in the
diagnostic process. There was no evident association
between the actual level of transmission intensity and
drug-prescribing behaviour across the sites: two thirds
of the RDT negative individuals received anti-malarial
drugs in the area of lowest endemicity. An official policy
change, where RDTs were provided and healthcare pro-
viders were advised to adhere to RDT results in pre-
scribing drugs was followed by lower anti-malarial
prescription rates and higher antibiotic prescription
rates in parasite negative children. This study indicates
that an official policy change may reduce the overuse of
anti-malarials, resulting in a more rational drug-pre-
scribing behaviour.
In this study, treatment policies are described in chil-
dren with reported fever visiting outpatient departments
of three district hospitals in regions of differing malaria
transmission intensity. Baseline diagnostic behaviour
was similar between hospitals and over-treatment,
defined as anti-malarial treatment of RDT-negative indi-
viduals, ranged from 68 - 90%, which is similar to pre-
vious studies [8,13,14]. Prior to policy change, these
RDT results were provided to have an objective indica-
tor of malaria infection for this study. The RDT was not
requested by the responsible clinical officer who mostly
based his or her diagnosis on clinical symptoms alone
and microscopic results were often ignored in the final
decision-making. Over-treatment was particularly com-
mon in Rubya and Biharamulo, areas where parasite
prevalence by RDT and transmission intensity by
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Figure 2 Rubya DDH after policy change. AM = anti-malarial treatment given; AB = antibiotics given; NT = no treatment installed; RDT =
rapid diagnostic test.
Table 2 Treatment practices in relation to malaria parasite prevalence by rapid diagnostic test (RDT)
Sumve DDH Biharamulo DDH Rubya DDH
Before policy change After policy change Before policy change After policy change
Reported fever 362 360 135 250 501
Proportion RDT+, % (n/N) 42.0% (152/362) 19.6% (67/341) 6.3% (8/127) 1.2% (3/250) 4.4% (22/501)
Anti-malarial treatment
RDT+, % (n/N)* 100% (152/152) 92% (62/67) 75.0% (6/8) 100% (3/3) 100% (22/22)
RDT-,% (n/N) ** 68.1% (143/210) 89.1% (244/274) 38.7% (46/119) 76.9% (190/247) 10.0% (48/479)
Antibiotic treatment
RDT+, % (n/N)
# 28.9% (44/152) 16.4% (11/67) 25.0% (2/8) 33.3% (1/3) 77.3% (17/22)
RDT-, % (n/N)
## 63.3% (133/210) 12.8% (35/274) 59.7% (71/119) 70.0% (173/247) 94.6% (453/479)
* proportion of RDT+ individuals who received anti-malarial treatment.
** proportion of RDT- individuals who received anti-malarial treatment.
# proportion of RDT+ individuals who received antibiotics.
## proportion of RDT- individuals who received antibiotics.
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current levels of malaria transmission intensity. Like
other recent studies [1,8,14], this study shows a discre-
pancy between the perceived and actual levels of trans-
mission intensity. While there was no evidence for
recent changes in transmission intensity in Rubya, trans-
mission intensity appeared to have dropped in Bihara-
mulo in the last decade. The reason for this change in
transmission is unknown, but has been observed before
in northern Tanzania [21].
Presumptive treatment of fevers with anti-malarials
may have a beneficial prophylactic effect that could also
result in a reduction in malaria transmission by reducing
the human infectious reservoir [6]. However, in a setting
like Rubya where transmission intensity is low, this ben-
eficial effect is unlikely. The diagnosis of malaria and
according treatment may simply be a ‘convenient’ clini-
cal strategy avoiding the more complicated search for
other causes of the presenting illness [26]. Treatment of
all febrile episodes as malaria is likely to result in under-
diagnosis of other fever-causing disorders such as child-
hood pneumonia [2]. In addition, there are financial
implications. Over-treatment will often be with the
highly effective, but expensive, artemether-lumefantrine
(AL). In the current study, all malaria episodes were
treated with AL. AL and other ACTs are 10-times more
e x p e n s i v et h a np r e v i o u s l yu s e dd r u g sa ss u l p h a d o x i n e -
pyrimethamine [27,28] making reliable diagnosis crucial
for cost-effective use [29]. Importantly, there is concern
for a reduced susceptibility of P. falciparum parasites
for ACT [30] and the spread of parasites with reduced
susceptibility to ACT may be enhanced by irrational
drug use [31]. Reports on allelic selection after arte-
mether-lumefantrine over-use [32] provide additional
warnings against over-use of ACT.
Microscopic examination of a blood smear is the gold
standard method for the diagnosis of malaria, but even
if microscopy is used, there can be substantial over-diag-
nosis of malaria [17]. In Sumve DDH and Rubya DDH
clinicians frequently requested blood slides, but also fre-
quently ignored negative results. In these hospitals up to
81% of the slide-negative individuals were treated with
anti-malarials. In Biharamulo DDH 79% of the children
were treated with anti-malarials while no lab-confirma-
tion was sought (i.e. no slide was requested). The Tan-
zanian Ministry of Health and Social Welfare
implemented a policy change in the Kagera Region to
tackle malaria over-diagnosis and over-treatment by
replacing routine microscopy with RDTs as main diag-
nostic tool. Although RDTs may not be 100% sensitive
in detecting (low-density) malaria infections [1], a pro-
spective study found that restricting anti-malarials to
RDT-positive individuals is a safe strategy in low ende-
mic areas that does not lead to excess mortality due to
false-negative results [33]. RDT results are objective and
can also be confirmed by the person responsible for the
clinical decision making who may not be confident with
microscopy. The two different RDTs used in this study
are both based on HRP-2 for parasite detection and
have similar sensitivity; we do not expect marginal dif-
ferences in RDT sensitivity to have influenced the treat-
ment prescribing behaviour. The results of this study
indicate an evident short-term impact on diagnostic
behaviour and treatment decisions, unlike results from a
previous study in Zambia [34]. In Rubya DDH, the pro-
portion of individuals receiving anti-malarials despite
negative RDTs was reduced seven-fold. This indicates
that clinicians appeared willing to trust the RDT result
in their decision-making, at least shortly after receiving
clear instructions from the Tanzanian Ministry of
Health. Presumptive treatment was not completely
abandoned but decreased substantially. It is encouraging
that antibiotic prescription increased in RDT-negative
individuals, indicating that alternative diagnoses and
treatment options are considered.
The current study was purely observational and no
attempts were made to change the clinical decision
making process during the study. The new government
guidelines were explained by the medical officers in
charge and information on the sensitivity of RDTs was
provided. Although an effect of the present study cannot
be ruled out completely, similar observational studies
showed no positive effect on diagnostic and drug-pre-
scribing behaviour [8,14]. Therefore, the impact of the
current observational study on treatment practices will
Figure 3 Age specific seroprevalence plots for AMA-1 for
Sumve, Biharamulo and Rubya. For Biharamulo two forces of
infection were fitted for the other two sites one force of infection
fitted the data best. The seroconversion rate (SCR, l) for Sumve was
0.082 (95% CI 0.063-0.11). For Biharamulo the SCR was 0.34 (95% CI
0.19-0.61) for the period up to 1999 (i.e. for individuals older than
10 years of age) but 0.019 (95% CI 0.011-0.035) for the period 1999-
2009. The SCR for Rubya was 0.041 (95% CI 0.029 - 0.058).
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provided by the government. There are conditions for
the policy change to work and keep working. First of all,
the hospital staff must be well trained and confident
regarding the new policy and new diagnostic test and
clear guidelines should also be provided on treatment
policies for RDT negative individuals. Secondly, the
RDTs must be available at all times, as well as anti-
malarial drugs and antibiotics. In Rubya DDH, RDTs
provided by the Tanzanian government were out of
stock in the beginning of February 2010. This is also
seen in other countries [34]. Consequently, this brings
the risk of hospital staff returning to their former diag-
nostic and drug-prescribing behaviour.
Conclusion
This study shows promising data on decrease of anti-
malarial drug-prescription. Larger prospective studies
are needed to confirm the current findings, to determine
the impact of the new policy on morbidity and mortality
and to assess the long-term impact of the described pol-
icy change. The current findings on rational drug-pre-
scribing behaviour in Tanzanian hospitals are promising.
Additional material
Additional file 1: Biharamulo DDH before policy change.
Additional file 2: Biharamulo DDH after policy change.
Additional file 3: Sumve DDH (no policy change).
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